Flu redux and RIT: Friendly fire in the treatment of low-grade lymphoma

Leo I. Gordon

doi:10.1182/blood-2005-03-1250

Flu redux and RIT: Friendly fire in the treatment of low-grade lymphoma

Leo I. Gordon

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

Abstract

Two reports describe the problem of secondary malignancies in patients with LGL. Bennett and colleagues find that I¹³¹ tositumomab (Bexxar) following alkylating agent therapy does not increase the risk of tMDS or tAML, while McLaughlin and colleagues find that this risk is increased following fludarabine-based therapy.

Original language	English (US)
Pages (from-to)	4543-4544
Number of pages	2
Journal	Blood
Volume	105
Issue number	12
DOIs	https://doi.org/10.1182/blood-2005-03-1250
State	Published - Jun 15 2005

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2005-03-1250

Cite this

@article{f0644cb8f72e4eb19dd874135978ad89,

title = "Flu redux and RIT: Friendly fire in the treatment of low-grade lymphoma",

abstract = "Two reports describe the problem of secondary malignancies in patients with LGL. Bennett and colleagues find that I131 tositumomab (Bexxar) following alkylating agent therapy does not increase the risk of tMDS or tAML, while McLaughlin and colleagues find that this risk is increased following fludarabine-based therapy.",

author = "Gordon, {Leo I.}",

year = "2005",

month = jun,

day = "15",

doi = "10.1182/blood-2005-03-1250",

language = "English (US)",

volume = "105",

pages = "4543--4544",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "12",

}

TY - JOUR

T1 - Flu redux and RIT

T2 - Friendly fire in the treatment of low-grade lymphoma

AU - Gordon, Leo I.

PY - 2005/6/15

Y1 - 2005/6/15

N2 - Two reports describe the problem of secondary malignancies in patients with LGL. Bennett and colleagues find that I131 tositumomab (Bexxar) following alkylating agent therapy does not increase the risk of tMDS or tAML, while McLaughlin and colleagues find that this risk is increased following fludarabine-based therapy.

AB - Two reports describe the problem of secondary malignancies in patients with LGL. Bennett and colleagues find that I131 tositumomab (Bexxar) following alkylating agent therapy does not increase the risk of tMDS or tAML, while McLaughlin and colleagues find that this risk is increased following fludarabine-based therapy.

UR - http://www.scopus.com/inward/record.url?scp=20444406389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444406389&partnerID=8YFLogxK

U2 - 10.1182/blood-2005-03-1250

DO - 10.1182/blood-2005-03-1250

M3 - Article

AN - SCOPUS:20444406389

SN - 0006-4971

VL - 105

SP - 4543

EP - 4544

JO - Blood

JF - Blood

IS - 12

ER -

Flu redux and RIT: Friendly fire in the treatment of low-grade lymphoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this